Immunotherapy for prostate cancer: Recent developments and future challenges

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 641-655

  Schweizer, Michael T ^a,b   Drake, Charles G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Immune checkpoints; Immunotherapy; Prostate cancer; T cell; Vaccine

Indexed keywords

ABIRATERONE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIGEN; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DNA VACCINE; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; KETOCONAZOLE; MDX 1105; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY PD 1; NIVOLUMAB; PIDILIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROSTVAC VF TRICOM; RILIMOGENE GALVACIREPVEC; RITUXIMAB; SIPULEUCEL T; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; ANDROGEN; TUMOR ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLITIS; DIARRHEA; DRUG TARGETING; HEPATITIS; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNE SYSTEM; LOW DRUG DOSE; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROSTATIC NEOPLASMS;

ANDROGENS; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 84905115620     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9479-8     Document Type: Review

References (120)

1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J Clin, 63(1), 11-30. doi:10.3322/caac.21166.
2. Huggins, C., & Hodges, C. V. (2002). Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol, 168(1), 9-12.
3. Schweizer, M. T., & Antonarakis, E. S. (2012). Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther AdvUrol, 4(4), 167-178. doi:10.1177/1756287212452196.
4. Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patientswith progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol, 26(7), 1148-1159. doi:10. 1200/jco.2007.12.4487.
5. Tannock, I. F., deWit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351(15), 1502-1512. doi:10.1056/NEJMoa040720. (Pubitemid 39315317)
6. Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351(15), 1513-1520. doi:10.1056/NEJMoa041318. (Pubitemid 39315318)
7. Kantoff, P.W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363(5), 411-422. doi:10.1056/NEJMoa1001294.
8. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376(9747), 1147-1154. doi:10.1016/s0140-6736(10)61389-x.
9. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364(21), 1995-2005. doi:10.1056/NEJMoa1014618.
10. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368(2), 138-148. doi:10.1056/NEJMoa1209096.
11. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367(13), 1187-1197. doi:10.1056/NEJMoa1207506.
12. Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fossa, S. D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 369(3), 213-223. doi:10.1056/NEJMoa1213755.
13. Aragon-Ching, J. B., Williams, K. M., & Gulley, J. L. (2007). Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci, 12, 4957-4971.
14. Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol, 8(1), 59-73. doi:10.1038/nri2216.
15. Drake, C. G. (2011). Radiation-induced immune modulation. In T. L. L. DeWeese & M. Laiho (Eds.), Molecular Determinants of Radiation Response (pp. 251-263). New York: Springer.
16. Delves, P. J.,&Roitt, I. M. (2000). The immune system. First of two parts. N Engl J Med, 343 (1), 37-49. doi :10.1056/nejm200007063430107.
17. Delves, P. J., & Roitt, I. M. (2000). The immune system. Second of two parts. N Engl J Med, 343(2), 108-117. doi:10.1056/nejm200007133430207.
18. Simeone, E., & Ascierto, P. A. (2012). Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol, 9(3), 241-247. doi:10.3109/1547691x. 2012.678021.
19. Korman, A. J., Peggs, K. S., & Allison, J. P. (2006). Checkpoint blockade in cancer immunotherapy. Adv Immunol, 90, 297-339. doi:10.1016/s0065- 2776(06)90008-x. (Pubitemid 43765802)
20. Kwek, S. S., Dao, V., Roy, R., Hou, Y., Alajajian, D., Simko, J. P., et al. (2012). Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol, 189(7), 3759-3766. doi:10.4049/jimmunol.1201529.
21. Kwek, S. S., Cha, E., & Fong, L. (2012). Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer, 12(4), 289-297. doi:10.1038/nrc3223.
22. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322(5899), 271-275. doi:10.1126/science.1160062.
23. Quezada, S. A., Peggs, K. S., Curran, M. A., & Allison, J. P. (2006). CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest, 116(7), 1935-1945. doi:10.1172/jci27745. (Pubitemid 44033317)
24. Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., et al. (2013). Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunol Res, 1(1), 32-42. doi:10.1158/2326-6066/CIR-13-0013.
25. Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med, 210(9), 1695-1710. doi:10.1084/jem.20130579.
26. Nemazee, D. (2006). Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol, 6(10), 728-740. doi:10.1038/nri1939.
27. Sheikh, N. A., Petrylak, D., Kantoff, P. W., Dela Rosa, C., Stewart, F. P., Kuan, L. Y., et al. (2013). Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother, 62(1), 137- 147. doi:10.1007/s00262-012-1317-2.
28. Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331(6024), 1565-1570. doi:10.1126/science.1203486.
29. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410(6832), 1107-1111. doi:10.1038/35074122. (Pubitemid 32391043)
30. Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., et al. (2005). Autoantibody signatures in prostate cancer. N Engl J Med, 353(12), 1224-1235. doi:10.1056/NEJMoa051931.
31. Drake, C.G., Doody, A. D., Mihalyo, M.A., Huang, C. T., Kelleher, E., Ravi, S., et al. (2005). Androgen ablationmitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell, 7(3), 239-249. doi:10.1016/j.ccr.2005.01.027. (Pubitemid 40568683)
32. Mercader, M., Bodner, B. K., Moser, M. T., Kwon, P. S., Park, E. S., Manecke, R. G., et al. (2001). T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A, 98(25), 14565-14570. doi:10.1073/pnas.251140998. (Pubitemid 33121432)
33. Kovacs, W. J., & Olsen, N. J. (1987). Androgen receptors in human thymocytes. J Immunol, 139(2), 490-493.
34. Viselli, S. M., Olsen, N. J., Shults, K., Steizer, G., & Kovacs, W. J. (1995). Immunochemical and flow cytometric analysis of androgen receptor expression in thymocytes. Mol Cell Endocrinol, 109(1), 19-26.
35. Cohen, J. H., Danel, L., Cordier, G., Saez, S., & Revillard, J. P. (1983). Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol, 131(6), 2767-2771. (Pubitemid 14208118)
36. Benten, W. P., Lieberherr, M., Giese, G., Wrehlke, C., Stamm, O., Sekeris, C. E., et al. (1999). Functional testosterone receptors in plasma membranes of T cells. FASEB J, 13(1), 123-133. (Pubitemid 29038282)
37. Pearce, P., Khalid, B. A.,&Funder, J.W. (1981). Androgens and the thymus. Endocrinology, 109(4), 1073-1077. (Pubitemid 11008285)
38. Kumar, N., Shan, L. X., Hardy, M. P., Bardin, C. W., & Sundaram, K. (1995). Mechanism of androgen-induced thymolysis in rats. Endocrinology, 136(11), 4887-4893.
39. Brelinska, R. (2003). Thymic epithelial cells in age-dependent involution. Microsc Res Tech, 62(6), 488-500. doi:10.1002/jemt.10410.
40. Sutherland, J. S., Goldberg, G. L., Hammett, M. V., Uldrich, A. P., Berzins, S. P., Heng, T. S., et al. (2005). Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol, 175(4), 2741-2753. (Pubitemid 41113891)
41. Olsen, N. J., Olson, G., Viselli, S. M., Gu, X.,&Kovacs, W. J. (2001). Androgen receptors in thymic epithelium modulate thymus size and thymocyte development. Endocrinology, 142(3), 1278-1283. (Pubitemid 32202839)
42. Dulos, G. J., & Bagchus, W. M. (2001). Androgens indirectly accelerate thymocyte apoptosis. Int Immunopharmacol, 1(2), 321-328.
43. Wilson, C. A., Mrose, S. A., & Thomas, D. W. (1995). Enhanced production of B lymphocytes after castration. Blood, 85(6), 1535-1539.
44. Viselli, S. M., Reese, K. R., Fan, J., Kovacs, W. J., & Olsen, N. J. (1997). Androgens alter B cell development in normal male mice. Cell Immunol, 182(2), 99-104. doi:10.1006/cimm.1997.1227. (Pubitemid 28133997)
45. Roden, A. C., Moser, M. T., Tri, S. D., Mercader, M., Kuntz, S.M., Dong, H., et al. (2004). Augmentation of Tcell levels and responses induced by androgen deprivation. J Immunol, 173(10), 6098-6108. (Pubitemid 39487766)
46. Marzo, A. L., Kinnear, B. F., Lake, R. A., Frelinger, J. J., Collins, E. J., Robinson, B.W., et al. (2000). Tumor-specific CD4+ Tcells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol, 165(11), 6047-6055.
47. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998). The central role of CD4(+) T cells in the antitumor immune response. J Exp Med, 188(12), 2357-2368. (Pubitemid 29028508)
48. Dobrzanski, M. J. (2013). Expanding roles for CD4 Tcells and their subpopulations in tumor immunity and therapy. Front Oncol, 3, 63. doi:10.3389/fonc.2013.00063.
49. Gannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A. M., & Saad, F. (2009). Characterization of the intraprostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods, 348(1-2), 9-17. doi:10.1016/j.jim.2009.06.004.
50. Antonarakis, E. S., Kibel, A., Tyler, R. C., McCoy, C., Wang, Y., Sheikh, N. A., et al. (2013). Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC) [abstract]. J Clin Oncol, 31, (suppl 6; abstr 34).
51. Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006). Mechanisms of immune evasion by tumors. Adv Immunol, 90, 51-81. doi:10.1016/s0065-2776(06) 90002-9. (Pubitemid 43765799)
52. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R.W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-723. doi:10.1056/NEJMoa1003466.
53. Robert, C., Thomas, L., Bondarenko, I., O'Day, S. M. D. J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 364(26), 2517-2526. doi:10.1056/NEJMoa1104621.
54. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., et al. (1997). Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A, 94(15), 8099-8103. (Pubitemid 27343783)
55. Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E.M., Greenberg, N. M., et al. (2000). Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res, 60(9), 2444-2448. (Pubitemid 30262435)
56. Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., et al. (2005). Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res, 11(2 Pt 1), 728-734. (Pubitemid 40116901)
57. Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., et al. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. doi:10.1093/annonc/mdt107.
58. Gerritsen, W. R., Kwon, E. D., Fizazi, K., Bossi, A., Van den Eertwegh, A., Logothetis, C., et al. (2013). CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castrationresistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT) [abstract]. European Cancer Congress, abstr 2850.
59. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8(8), 793-800. doi:10.1038/nm730.
60. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A, 99(19), 12293-12297. doi:10.1073/pnas.192461099.
61. Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., et al. (2012). Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistancemechanism of immune escape. Sci TranslMed, 4(127), 127ra-137ra. doi:10.1126/scitranslmed. 3003689.
62. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., et al. (2010). Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer, 116(7), 1757-1766. doi:10.1002/cncr.24899.
63. Barach, Y. S., Lee, J. S., & Zang, X. (2010). T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med. doi:10.1016/j.molmed.2010.09.006.
64. Sfanos, K. S., Bruno, T. C., Meeker, A.K., De Marzo, A.M., Isaacs, W. B., & Drake, C. G. (2009). Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate, 69(15), 1694-1703. doi:10.1002/pros.21020.
65. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366(26), 2443-2454. doi:10.1056/NEJMoa1200690.
66. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 366(26), 2455-2465. doi:10.1056/ NEJMoa1200694.
67. Weiner, L. M., Surana, R., & Wang, S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol, 10(5), 317-327. doi:10.1038/nri2744.
68. Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011). Cancer immunotherapy comes of age. J Clin Oncol, 29(36), 4828-4836. doi:10.1200/jco.2011.38.0899.
69. Mellman, I., Coukos, G., & Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature, 480(7378), 480-489. doi:10.1038/nature10673.
70. Drake, C. G. (2010). Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol, 10(8), 580-593. doi:10.1038/nri2817.
71. Banchereau, J., & Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature, 392(6673), 245-252. doi:10.1038/32588.
72. Shurin, M. R. (1996). Dendritic cells presenting tumor antigen. Cancer Immunol Immunother, 43(3), 158-164.
73. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., et al. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol, 18(23), 3894-3903.
74. Madan, R. A., Gulley, J. L., & Kantoff, P.W. (2013). Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J, 19(1), 50-58. doi:10.1097/PPO.0b013e31828160a9.
75. Huber, M. L., Haynes, L., Parker, C., & Iversen, P. (2012). Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst, 104(4), 273-279. doi:10.1093/jnci/djr514.
76. Mackall, C. L., Hakim, F. T., & Gress, R. E. (1997). Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol, 9(6), 339-346. doi:10.1006/smim.1997.0091. (Pubitemid 28021491)
77. Drake, C. G. (2012). Re: interdisciplinary critique of sipuleucel-Tas immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst, 104(18), 1422. doi:10.1093/jnci/djs340. author reply 1422-1423.
78. Gulley, J. L., Leitman, S. F., Dahut, W., & Schlom, J. (2012). Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst, 104(14), 1106. doi:10.1093/jnci/djs280. author reply 1109-1112.
79. Simons, J. W., Carducci, M. A., Mikhak, B., Lim, M., Biedrzycki, B., Borellini, F., et al. (2006). Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res, 12(11 Pt 1), 3394-3401. doi:10.1158/1078-0432.ccr-06-0145.
80. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A, 90(8), 3539-3543. (Pubitemid 23111402)
81. Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007). A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res, 13(6), 1810-1815. doi:10.1158/1078-0432.ccr-06-2318. (Pubitemid 46952950)
82. Small, E. J., Demkow, T., Gerritson, W. R., Rolland, F., Hoskin, P., Smith, D. C., et al. (2009). A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [Abstract]. American Society of Clinical Oncology Genitourinary Cancers Symposium, (Abstr 9).
83. Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H. R., Goldberg, M. V., et al. (2009). Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res, 69(10), 4309-4318. doi:10.1158/0008-5472.can-08-4102.
84. Arlen, P.M., Gulley, J. L., Madan, R. A., Hodge, J.W.,&Schlom, J. (2007). Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol, 27(5), 451-462.
85. Harrington, L. E., Most Rv, R., Whitton, J. L.,& Ahmed, R. (2002). Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol, 76(7), 3329-3337. (Pubitemid 34224535)
86. Madan, R. A., Arlen, P.M., Mohebtash, M., Hodge, J.W.,&Gulley, J. L. (2009). Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs, 18(7), 1001-1011. doi:10.1517/13543780902997928.
87. Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y. J., Sweeney, C., et al. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 22(11), 2122-2132. doi:10.1200/jco.2004.08.083. (Pubitemid 41095145)
88. Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y. J., Sweeney, C. J., et al. (2005). Phase II prime/boost vaccination using poxviruses expressing PSA in hormone-dependent prostate cancer: follow-up clinical results from ECOG 7897 [abstract]. J Clin Oncol, 23(16S), 4501.
89. Alam, S., & McNeel, D. G. (2010). DNAvaccines for the treatment of prostate cancer. Expert Rev Vaccines, 9(7), 731-745. doi:10.1586/erv.10.64.
90. Becker, J. T., Olson, B. M., Johnson, L. E., Davies, J. G., Dunphy, E. J., & McNeel, D. G. (2010). DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother, 33(6), 639-647. doi:10.1097/CJI.0b013e3181dda23e.
91. McNeel, D. G., Dunphy, E. J., Davies, J. G., Frye, T. P., Johnson, L. E., Staab, M. J., et al. (2009). Safety and immunological efficacy of a DNAvaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol, 27(25), 4047-4054. doi:10.1200/jco.2008.19.9968.
92. Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J., Kussie, P., & Ferguson, K. M. (2005). Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 7(4), 301-311. doi:10.1016/j.ccr.2005.03.003. (Pubitemid 40544648)
93. Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med, 6(4), 443-446. doi:10.1038/74704. (Pubitemid 30208162)
94. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 367(19), 1783-1791. doi:10.1056/NEJMoa1209124.
95. Akhtar, N. H., Pail, O., Saran, A., Tyrell, L.,&Tagawa, S. T. (2012). Prostate-specific membrane antigen-based therapeutics. Adv Urol, 2012, 973820. doi:10.1155/2012/973820.
96. Morris, M. J., Divgi, C. R., Pandit-Taskar, N., Batraki, M., Warren, N., Nacca, A., et al. (2005). Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res, 11(20), 7454-7461. doi:10.1158/1078-0432.ccr- 05-0826. (Pubitemid 41507706)
97. Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., & Goldsmith, S. J. (2005). Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J ClinOncol, 23(21), 4591-4601. doi:10.1200/jco.2005.05.160. (Pubitemid 46224061)
98. Hurwitz, A. A., Yu, T. F., Leach, D. R., & Allison, J. P. (1998). CTLA-4 blockade synergizes with tumor-derived granulocytemacrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A, 95(17), 10067-10071. (Pubitemid 28415295)
99. van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colonystimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med, 190(3), 355-366.
100. Woo, S. R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., et al. (2012). Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res, 72(4), 917-927. doi:10.1158/0008-5472.can-11-1620.
101. Fong, L., Kwek, S. S., O'Brien, S., Kavanagh, B., McNeel, D. G., Weinberg, V., et al. (2009). Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res, 69(2), 609-615. doi:10.1158/0008-5472.can-08-3529.
102. van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J., van der Sluis, T. M., et al. (2012). Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol, 13(5), 509-517. doi:10.1016/s1470-2045(12)70007-4.
103. Harzstark, A. L., Fong, L., Weinberg, V. K., Ryan, C. J., Lin, A.M., Sun, J., et al. (2010). Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC) [Abstract]. J Clin Oncol 28:15s, 2010 (suppl; abstr 4689)
104. Gerritsen, W. R., van den Eertwegh, A. J., de Gruijl, T. D., Giaccone, G., Scheper, R. J., Sacks, N., et al. (2007). Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) [Abstract]. J Clin Oncol 25:18s (suppl; abstr 5120).
105. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., & Kroemer, G. (2008). The anticancer immune response: indispensable for therapeutic success? J Clin Invest, 118(6), 1991-2001. doi:10.1172/jci35180. (Pubitemid 351872317)
106. Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., et al. (2010). Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol, 22(3), 113-124. doi:10.1016/j.smim.2010.03.001.
107. Tanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009). Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res, 69(17), 6978-6986. doi:10.1158/0008- 5472.can-09-1101.
108. Formenti, S. C.,&Demaria, S. (2013). Combining radiotherapy and cancer immunotherapy: a paradigmshift. J Natl Cancer Inst, 105(4), 256-265. doi:10.1093/jnci/djs629.
109. den Boer, A. T., van Mierlo, G. J., Fransen, M. F., Melief, C. J., Offringa, R., & Toes, R. E. (2004). The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol, 172(10), 6074-6079. (Pubitemid 38621209)
110. Finn, O. J. (2003). Cancer vaccines: between the idea and the reality. Nat Rev Immunol, 3(8), 630-641. doi:10.1038/nri1150.
111. Gulley, J. L., Arlen, P. M., Madan, R.A., Tsang, K. Y., Pazdur, M. P., Skarupa, L., et al. (2010). Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother, 59(5), 663-674. doi:10.1007/s00262-009-0782-8.
112. Motoyoshi, Y., Kaminoda, K., Saitoh, O., Hamasaki, K., Nakao, K., Ishii, N., et al. (2006). Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep, 16(1), 141-146.
113. Mole, R. H. (1953). Whole body irradiation; radiobiology or medicine? Br J Radiol, 26(305), 234-241.
114. Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., et al. (2004). Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys, 58(3), 862-870. doi:10.1016/j.ijrobp.2003.09.012. (Pubitemid 38221143)
115. Chi, K. H., Liu, S. J., Li, C. P., Kuo, H. P., Wang, Y. S., Chao, Y., et al. (2005). Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother, 28(2), 129-135. (Pubitemid 40328199)
116. Finkelstein, S. E., Iclozan, C., Bui, M. M., Cotter, M. J., Ramakrishnan, R., Ahmed, J., et al. (2012). Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys, 82(2), 924-932. doi:10.1016/j.ijrobp.2010.12.068.
117. Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., et al. (2010). In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol, 28(28), 4324-4332. doi:10.1200/jco.2010.28.9793.
118. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A.M., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. doi:10.1056/NEJMoa1302369.
119. Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl JMed. doi:10.1056/NEJMoa1305133.
120. Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbe, C., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res, 15(23), 7412-7420. doi:10.1158/1078-0432.ccr-09-1624.